JMJD6 Antibody (YA5153)

Cat. No.: HY-P85461: Data Sheet User Guide for Antibodies
FAQs
Technical Support

JMJD6 Antibody (YA5153) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to JMJD6.

For research use only. We do not sell to patients.

Size		Stock
50 μL		Get quote
100 μL		Get quote

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

JMJD6 Antibody (YA5153) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to JMJD6.

Host

Mouse

Clonality

Monoclonal

Molecular Weight

Predicted band size: 46 kDa;

Species Reactivity

Human, Mouse, Rat, Bovine, Dog

SwissProt ID

Q6NYC1

Gene ID

23210 [NCBI]

Immunogen

Purified recombinant human PSR (N-terminus) protein fragments expressed in E.coli.

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:1000-1:2000
ICC/IF ICC/IF: Immunocytochemistry/Immunofluorescence	1:100-1:500

Purity	affinity purified.	Conjugation	Non-conjugated
Modification	Unmodified

Appearance

Liquid

Formulation

Supplied in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：Dioxygenase that can both act as a arginine demethylase and a lysyl-hydroxylase (PubMed:17947579, PubMed:20684070, PubMed:21060799, PubMed:22189873, PubMed:24498420). Acts as a lysyl-hydroxylase that catalyzes 5-hydroxylation on specific lysine residues of target proteins such as U2AF2/U2AF65 and LUC7L2. Regulates RNA splicing by mediating 5-hydroxylation of U2AF2/U2AF65, affecting the pre-mRNA splicing activity of U2AF2/U2AF65 (PubMed:19574390). Hydroxylates its own N-terminus, which is required for homooligomerization (PubMed:22189873). Plays a role in the regulation of nucleolar liquid-liquid phase separation (LLPS) by post-translationally modifying LIAT1 at its lysine-rich domain which inhibits LIAT1 nucleolar targeting (By similarity). In addition to peptidyl-lysine 5-dioxygenase activity, may act as an RNA hydroxylase, as suggested by its ability to bind single strand RNA (PubMed:20679243, PubMed:29176719). Also acts as an arginine demethylase which preferentially demethylates asymmetric dimethylation (PubMed:17947579, PubMed:24360279, PubMed:24498420). Demethylates histone H3 at 'Arg-2' (H3R2me) and histone H4 at 'Arg-3' (H4R3me), including mono-, symmetric di- and asymmetric dimethylated forms, thereby playing a role in histone code (PubMed:17947579, PubMed:24360279). However, histone arginine demethylation may not constitute the primary activity in vivo (PubMed:17947579, PubMed:21060799, PubMed:22189873). In collaboration with BRD4, interacts with the positive transcription elongation factor b (P-TEFb) complex in its active form to regulate polymerase II promoter-proximal pause release for transcriptional activation of a large cohort of genes. On distal enhancers, so called anti-pause enhancers, demethylates both histone H4R3me2 and the methyl cap of 7SKsnRNA leading to the dismissal of the 7SKsnRNA:HEXIM1 inhibitor complex. After removal of repressive marks, the complex BRD4:JMJD6 attract and retain the P-TEFb complex on chromatin, leading to its activation, promoter-proximal polymerase II pause release, and transcriptional activation (PubMed:24360279). Demethylates other arginine methylated-proteins such as ESR1 (PubMed:24498420). Has no histone lysine demethylase activity (PubMed:21060799). Required for differentiation of multiple organs during embryogenesis. Acts as a key regulator of hematopoietic differentiation: required for angiogenic sprouting by regulating the pre-mRNA splicing activity of U2AF2/U2AF65 (By similarity). Seems to be necessary for the regulation of macrophage cytokine responses (PubMed:15622002)

Subcellular Localization：Nucleus, nucleoplasm; Nucleus, nucleolus; Cytoplasm

Expression：
Tissue_specificity:It is highly expressed in the heart, skeletal muscle, and kidneys. Its expression levels are moderate to low in the brain, placenta, lungs, liver, pancreas, spleen, thymus, prostate, testes, and ovaries. It is upregulated in many cases of chronic pancreatitis. It is expressed in lactating thymic epithelial cells.

Induction:Up-regulated upon cytokine treatment, but not upon TNF treatment

Isoforms & Post-Translational Modification：Q6NYC1 has 3 isomers: Q6NYC1-1: 46462 Da (predicted); Q6NYC1-2: 43109 Da (predicted); Q6NYC1-3: 47626 Da (predicted).
Hydroxylates its own N-terminus; hydroxylation is required for homooligomerization

Subunit：Homooligomerizes; requires lysyl-hydroxylase activity (PubMed:22189873, PubMed:24360279). Interacts with LUC7L2, LUC7L3 and U2AF2/U2AF65 (PubMed:19574390). Interacts with CDK9 and CCNT1; the interaction is direct with CDK9 and associates the P-TEFb complex when active (PubMed:24360279). Interacts (via JmjC and N-terminal domains) with BRD4 (via NET domain); the interaction is stronger in presence of ssRNA and recruits JMJD6 on distal enhancers (PubMed:21555454, PubMed:24360279, PubMed:29176719). Interacts with ARGLU1; interaction may be involved in ARGLU1-mediated modulation of alternative splicing (PubMed:30698747)

Synonyms

JMJD6; KIAA0585; PTDSR; Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6; Histone arginine demethylase JMJD6; JmjC domain-containing protein 6; Jumonji domain-containing protein 6; Lysyl-hydroxylase JMJD6; Peptide-lysine 5-diox

Documentation

User Guide for Antibodies (1077 KB)